The characteristics of patients who discontinue their dying process – an observational study at a single university hospital centre by Christian Schulz et al.
RESEARCH ARTICLE Open Access
The characteristics of patients who
discontinue their dying process – an
observational study at a single university
hospital centre
Christian Schulz1*, Daniel Schlieper1, Christiane Altreuther1, Manuela Schallenburger1, Katharina Fetz1,2
and Andrea Schmitz1,3
Abstract
Background: End-of-life integrated care plans are used as structuring tools for the care of the dying. A widely
adopted example is the Liverpool Care Pathway for the Dying Patient (LCP). Recently, several concerns were raised
about LCP care, such as a worry that diagnosis of dying might be leading to a self-fulfilling trajectory, including
hastening of death. However, data on rates of discontinuation of LCP care are lacking. In an observational study, we
therefore investigated the incidence, features and trajectory of patients who were discontinued from the LCP. We
hypothesised that (1) it is common to discontinue patients from the LCP, (2) quality of life does not decrease for
discontinued LCP patients, and (3) discontinued patients live longer than patients who remain within LCP care.
Methods: All adult patients who were diagnosed as dying in a German university hospital specialized palliative care
unit were included in 2013 and 2014. Actuarial estimation of survival prognostication tools and a number of quality
of life indicators were used for data collection. Survival time was analysed using Kaplan-Meier estimates. Group differences
in quality of life were tested using multivariate analysis of variance.
Results: 159 patients were included in a digital version of the LCP. 15 patients (9.4 %) were discontinued
later. Quality of life did not decrease for discontinued patients during LCP care (p = 0.16). LCP discontinued
patients lived significantly longer than the remaining LCP subgroup (difference of means 296 hours, 95 %
confidence interval 105.5 to 451.5 hours; difference of survival function estimates p < 0.0001).
Conclusions: When patients are diagnosed as dying, death is not the inevitable outcome of an end-of-life
integrated care plan such as the LCP. Instead, it is common to discontinue the LCP care. Regular careful
interprofessional assessments are important for identifying those patients who need to be discontinued from
their end-of-life care plan. In this study, we found no evidence for harm by the LCP. We conclude that a
correctly applied integrated care plan can be useful to provide good and safe care for the dying.
Trial registration: Internal Clinical Trial Register of the Medical Faculty, Heinrich Heine University Düsseldorf,
No. 2015053680 (22 May 2015).
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Background
For dying patients, receiving the best possible quality of
care is considered a basic human right [1]. An end-of-
life care plan, such as the Liverpool Care Pathway for
the Dying Patient (LCP) [2], is a complex intervention to
structure the care of the dying in the last hours or days
of life [3]. The original aim of the LCP was to transfer
care practice from a hospice setting to other care set-
tings [2]. The LCP was primarily meant to measure out-
comes and to facilitate audit rather than to influence
outcomes [2, 4, 5]. However, implementing interventions
that assess the quality of life in palliative care does result
in improved outcomes [6], and the use of an integrated
care pathway promotes good practice. Therefore, it is
conceivable that the LCP improves both the efficiency
and quality of care and ensures good communication
within the team and with patients and their relatives [7].
A recent Cochrane systematic review [8] found little
evidence that an integrated care pathway during the
dying phase improves outcomes: Only one cluster ran-
domized trial showed that respect, dignity and kindness
as well as control of dyspnoea were significantly im-
proved by the LCP, while the overall quality of care was
not significantly different [9]. However, this study was
underpowered and may have missed outcome differ-
ences [9]. In non-controlled before and after studies
[10], the use of LCP was shown to improve coordination
of care [11], communication within the interdisciplinary
team [12], symptom control [13], documentation [12, 13],
use of appropriate medication [12, 14], bereavement
levels of relatives [15], communication with patients
or families [12, 16] and family support [11]. Focus
group meetings of nurses and physicians indicate that
the use of LCP strengthens the interprofessional team-
work [17, 18].
The LCP is used internationally in at least 22 countries
[19]. In England, the LCP was recognized as a model of
best practice in 2001 and was widely implemented in the
following years [20, 21]. However, according to a
commissioned report by Neuberger et al., the LCP was
not applied properly in a number of places [22], and the
LCP was phased out in the United Kingdom in 2014
[23, 24]. Notably, even the authors of this report,
along with other commentators, stressed the point that if
correctly implemented the LCP use resulted in patients
dying a “peaceful and dignified death” [22, 25–31].
A strict requirement of the LCP is the regular re-
assessment of the diagnosis of the dying process [2].
Many palliative care professionals can describe anecdotal
experiences, in which patients have stabilised during the
dying phase and continued living for a period of time.
Hence, despite being called “pathway”, the LCP is not
designed as a one-way street with a linear trajectory, but
provides decision points and loops (see Fig. 1).
How many patients recover while in the LCP? How
often is the LCP discontinued in practice? Data answer-
ing these questions are lacking and have been considered
a research priority [22, 32]. Consequently, we conducted
an open cohort study to investigate the incidence, fea-
tures and trajectory of patients who were discontinued
from the LCP. The setting is a university hospital
specialized palliative care unit (SPCU) in Germany.
Our objective was to analyse the characteristics of
LCP patients, including frequency for and reasons of
LCP discontinuation, quality of life, and survival times
of discontinued LCP patients. Our hypotheses were
(1) it is common to discontinue patients from the
LCP, (2) quality of life does not decrease for discon-
tinued LCP patients, and (3) discontinued patients
live longer (in comparison to the patients who stay
on the LCP).
Methods
We followed the STROBE guidelines for reporting ob-
servational cohort studies [33]. This study was approved
by the ethics board of the Medical Faculty of Heinrich
Heine University Düsseldorf (protocol number 5003, ap-
proved 02.03.2015). Given the retrospective and observa-
tional nature of our study, the ethics board waived the
requirement for informed consent.
Study design
We used an open cohort study design that is appropriate
to follow a group of patients with different outcomes
(death in LCP vs. LCP discontinued) over time. We
assessed the survival time as primary outcome along
with prognostication and a number of quality of life in-
dicators as secondary outcomes. The cohort included all
palliative care patients (age > 18) who were admitted to
the 8-beds specialized palliative care unit (SPCU) at the
University Hospital Düsseldorf, Germany, and who were
diagnosed as dying between January 2013 and December
2014 (Fig. 2). Standard care involved careful assessment
of symptom burden, development of an interprofessional
treatment plan, treatment of symptoms on the physical,
psychological, social and spiritual level, as well as daily
team meetings for re-evaluation, and 24-hour specialist
palliative care backup.
All patients were followed-up until their death, includ-
ing those for whom the LCP was discontinued and who
were discharged from the SPCU. Data were collected at
SPCU admission (baseline, t1), at the time of entry into
the LCP (t2) and at the time of LCP discontinuation
(t3). At baseline, three actuarial estimation of survival
prognostication tools were used to estimate the risk of
death and for calculating potential confounding or mod-
eration: Palliative Prognostic Index (PPI) [34], Palliative
Prognostic Score (PaP-S) [35] and Palliative Performance
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Scale (PPS) [36]. Clinician’s prediction of survival was
used to group patients along the care trajectory using
four distinct expectation categories of palliative stages:
rehabilitation phase, early end of life phase, late end of
life phase and terminal phase [34, 37, 38]. These categor-
ies and the prognostication tools served to characterize
the cohort and for statistical analysis. In the context of
this study, these instruments were of negligible impact
on the care the patients received. Additionally, quality of
life was measured using validated instruments for daily
living abilities: Karnofsky index [39], Eastern Coopera-
tive Oncology Group (ECOG) scale [40], Barthel index
[41] and activities and existential experiences of life scale
(AEDL) [42].
Symptom burden was assessed by a palliative care
nurse using single items with 5-point-Likert scales (0–4)
for ten major symptoms in palliative care (vigilance, de-
lirium, restlessness, sweating, fatigue, nausea, vomiting,
dyspnoea, coughing and itching). Constipation was re-
corded as a dichotomous variable (0–1). Pain was mea-
sured on a numeric rating scale from 0 to 10 and
assessed by self-rating if possible, or by a palliative care
nurse. The sum of these scores provided the overall
symptom score (range 0–51). Furthermore, selected
items were grouped to four core domains of symptoms
to generate sub-scores: psychological burden (vigilance,
delirium and restlessness; 0–12); nausea/vomiting (0–8);
dyspnoea (0–4) and pain (0–10) for longitudinal assess-
ment of symptom burden over time (t1, t2, t3).
Patients who were diagnosed as dying according to all
four criteria by Ellershaw and Ward [2] (patient becomes
bedbound, semicomatose, able to take only sips of fluid
and no longer able to take oral drugs) were included into
the LCP (version 12 in German) [43, 44]. Decreased
functional status over time and not having an acute re-
versible reason for their decline were two additional as-
pects considered by the interprofessional team (IPT).
The patient assessment was documented and mutually
agreed by a minimum of one physician and one pallia-
tive care nurse. We used an in-house developed digital
version of the LCP, which was integrated into the digital
hospital patient management system (Medico, Cerner,
North Kansas City, MO, USA). Digital patient chart in-
formation and written team discussion notes were used
Fig. 1 The trajectory of the Liverpool Care Pathway (LCP) [2, 44]. Routine interprofessional team (IPT) reassessment identifies patients who are no
longer classified as dying
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to evaluate the reasons in which the LCP was discontin-
ued. Qualitative thematic analysis was used to group
qualitative findings.
Statistical analysis
All statistical tests were performed using SPSS version
22.0 for Windows (IBM, Armonk, NY, USA). Demo-
graphic variables and psychometric scales are pre-
sented as median and range. Prior to further analysis,
sample data was tested for homogeneity of variance
using Levene’s test.
Possible confounding variables concerning the exclu-
sion from the LCP were identified by analysing descrip-
tive data. Differences in the subgroup medians (died in
LCP vs. discontinued) greater than 15 % were considered
as possible confounders. The respective measurements,
i. e., PPI score, Karnofsky index, LCP duration, disease
category (cancer/non-cancer), were controlled for their
predictive value concerning the exclusion from the LCP
by means of binary logistic regression analyses.
For comparison of time of measurement for the symp-
tom burden sub scores (psychological symptoms, nausea/
vomiting, pain and dyspnoea) a multivariate analysis of
variance with repeated measurements using Pillai’s trace
with the symptom burden subscores as the dependent
variables and time of measurement as within-subjects-
factor was conducted. Survival curves were obtained
using the Kaplan-Meier method and comparisons between
subgroups were calculated by Breslow test (generalised
Wilcoxon test). For all tests p < 0.05 was considered statis-
tically significant.
Results
We observed SPCU patients within the LCP between
January 2013 and December 2014. From a total of 382
patients who were treated at the SPCU, 239 patients
died during the study period (62.6 %). One patient was
excluded because he was too young. 238 patients were
eligible cohort members, of those, 159 (67 %) patients
were included in the LCP (Figure 2). The LCP patients
form our final sample. The characteristics are shown in
Table 1. Of the remaining 79 non-included patients, the
majority died without prior team expectation of
imminent death (57 patients, 72 %) and in some cases
no IPT consensus on the diagnosis of dying was reached
during the primary LCP assessment (18 patients, 23 %).
The median time span between SPCU admission and LCP
inclusion was 99 hours (range 0–766 hours). The
median LCP duration for included patients was
78.9 hours (range 0–695 hours).
Fig. 2 Flow chart of the cohort study design
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LCP discontinuation: rate and reasons
A considerable number of LCP patients (15 out of
159; 9.4 %) were discontinued from the LCP after
routine reassessment. Table 2 compares the characteris-
tics of the 144 patients who died on the LCP with the sub-
group of 15 discontinued LCP patients. The IPT
documented the reasons for LCP discontinuation as: im-
proved vigilance (n = 9), eating and drinking again (n = 8),
general functional improvement (n = 6), patient communi-
cates again (n = 6), regained ability to swallow (n = 4), pa-
tient interacts with family (n = 2), team opinion equivocal
(n = 2) and can leave the bed again (n = 1).
None of our ancillary analyses concerning confound-
ing or moderation of LCP exclusion showed significant
predictive values (all p values > 0.05). The test statistics
and p-values of the binary logistic regression analyses
are shown in Table 3.
Nine of the 15 patients re-entered the LCP at a later
point (median interval until reinclusion 188 hours; range
16–602 hours; second LCP duration: median 11 hours;
range 6–195 hours). Three patients died without re-
entering the LCP and three patients were discharged
from the hospital.
Survival time of discontinued patients
Taking LCP initiation as the starting point, median
survival time for the 15 discontinued patients was
318 hours (95 % confidence interval, CI, 158.94 to




Age (years)a 71 (28–97)
SPCU stay (hours)a 146 (3–985)
Gender
Female 85 (53.5 %)
Male 74 (46.5 %)
Religion n = 159
Roman-catholic 70 (44 %)
Evangelical 43 (27 %)
Muslim 7 (4 %)
Other or unknown 5 (2 %)
None 34 (21 %)
Advanced directives n = 159
Patient will 69 (43 %)
Health care proxy 66 (42 %)
Disease n = 159
Cancer 135 (85 %)
Gastrointestinal 29 (18 %)
Haematological 22 (14 %)
Lung 18 (11 %)
Urogenital 16 (10 %)
Gynaecological 14 (9 %)
Ear-nose-throat 6 (4 %)
Unknown primary 17 (11 %)
Other 13 (8 %)
Non-cancer 24 (15 %)
Multi-organ failure 7 (4 %)
Central nervous system 7 (4 %)
Cardiovascular 6 (4 %)
Other 3 (2 %)
Prognostic scores (on admission)
PPI (0–15) n = 78
1–5 (>3 weeks) 18 (23 %)
6–15 (<3 weeks) 60 (77 %)
PaP-S 30 days survival (0–17.5) n = 79
>70 % (0–5.5) 13 (17 %)
30–70 % (6–11) 30 (38 %)
<30 % (11.5–17.5) 36 (46 %)
PPS (0–100 %) n = 83
>50 % 4 (5 %)
30–50 % 37 (38 %)
10–20 % 42 (51 %)
Palliative stage n = 132
Table 1 Description of the sample (Continued)
Rehabilitation phase 3 (2.3 %)
Early end of life phase 34 (25.8 %)
Late end of life phase 81 (61.4 %)
Terminal phase 14 (10.6 %)
Quality of life (on admission)
Karnofsky (0–100 %) n = 76
<30 % 55 (72.4 %)
>30 % 21 (27.6 %)
Data not available 83 (52 %)
ECOGa [0–5] 4 (1–4), n = 140
Barthela [0–100] 20 (0–95), n = 150
AEDLa [0–36] 18 (3–36), n = 159
Symptom burdena n = 159
Total score (0–51) 15 (5–30)
Psychological burden (0–12) 4 (0–12)
Dyspnoea (0–4) 2 (0–4)
Nausea/vomiting (0–8) 0 (0–7)
Pain (0–10) 3 (1–9)
aMedian, range
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477.06) and 22 hours for the 144 patients who stayed
on the LCP (95 % CI 18.47 to 25.53). Figure 3 shows
the Kaplan-Meier survival plot of the survival time
for all LCP patients, comparing patients whose LCP
care was discontinued to patients who stayed on the
LCP. The overall survival time difference was signifi-
cant in a Breslow test (χ2(1) = 26.85; p < 0.0001).
Quality of life over time
In the dying phase, symptom burden is a good surrogate
indicator for health-related quality of life [45–47]. We
assessed the accumulated symptom burden for twelve
different symptoms (vigilance, delirium, restlessness,
sweating, fatigue, nausea, vomiting, dyspnoea, coughing,
itching, constipation and pain) for three time points (t1, ad-
mission on ward; t2, LCP entry; t3, LCP discontinuation).
To analyse the symptom burden in detail, we assessed four
core domains of symptom burden (psychological distress,
nausea/vomiting, dyspnoea and pain) over time for those
15 patients who were discontinued from the LCP (Fig. 4).
A multivariate analysis of variance with repeated measure-
ment using Pillai’s trace showed no significant change of
the symptom burden during LCP care (V = 0.56; F (8,7) =
1.11; p = 0.45).
Discussion
Diagnosing dying is a complex issue and sometimes a
mystery [34, 48, 49]. We hypothesised that if applied ad-
equately, it is a common finding to discontinue patients
from an integrated care pathway for dying patients such
as the LCP because they seem to be no longer diagnosed
as dying. This hypothesis was confirmed. Given that dis-
continuation nearly exclusively equals evidence of per-
formance improvement in those patients, we further
hypothesised that discontinued patients live longer than
those who stay on the LCP. This hypothesis was con-
firmed as well. We found no evidence for a decline in
quality of life after discontinuation of the LCP.
The majority of discontinued patients (n = 9; 60 %) re-
entered LCP care at a later point in time during the
same admission period, while three patients died without
prior re-diagnosing of dying by the IPT. In this second
LCP care, patients died after a short period of time (me-
dian 11 hours). This finding demonstrates that even
those, whose LPC care was discontinued, were indeed at
a very late stage of their life. However and importantly,
those three patients who were discharged after discon-
tinuation (<2 % of total LCP sample) lived on for up to
13 weeks, which suggests that in a small proportion of
patients diagnosing dying remains uncertain, even in an
interprofessional, highly experienced team.
To our knowledge, this is the first study in the context
of recent palliative care literature reporting on instances
where “patients predicted as imminently dying have not
died within that care episode” [32] and, therefore, is a
direct response to the call for urgently needed research
in the field of end-of-life care.
Table 2 Comparison of patients who died during LCP care vs
LCP-discontinued patients
Died Discontinued
Number (n) 144 15
No IPT consensus on LCP - 2 (13 %)
Patient characteristics
Age (years)a 69.5 (28–97) 74 (51–87)
SPCUb stay (hours)a 130 (3–941) 355 (52–985)
Time on LCP (hours)a,c 22.5 (0–240) 46 (12–143)
Gender
Female 78 (54 %) 7 (47 %)
Male 66 (46 %) 8 (53 %)
Disease
Cancer 124 (86 %) 11 (73 %)
Non-cancer 20 (14 %) 4 (27 %)
Prognostic scoresd
PPI n = 68 n = 10
1–5 (>3 weeks) 14 (20.6 %) 4 (26.7 %)
6–15 (<3 weeks) 54 (79.4 %) 6 (60 %)
PaP-S n = 72 n = 7
>70 % (0.5–5.0) 12 (16.7 %) 1 (14.3 %)
30–70 % (6.0–11.0) 27 (37.5 %) 3 (42.9 %)
<30 % (11.5–17.5) 33 (45.8 %) 3 (42.9 %)
PPS n =73 n = 10
100–60 % 2 (2.7 %) 2 (20 %)
50–30 % 35 (47.9 %) 2 (20 %)
10–20 % 36 (49.3 %) 6 (60 %)
Palliative stage n = 120 n = 12
Rehabilitation phase 2 (1.7 %) 1 (8.3 %)
Early end of life phase 30 (25.0 %) 4 (33.3 %)
Late end of life phase 75 (62.5 %) 6 (50 %)
Terminal phase 13 (10.8 %) 1 (8.3 %)
Quality of lifed
Karnofsky n = 69 n = 7
>30 % 20 (29 %) 1 (14 %)
<30 % 49 (71 %) 6 (86 %)
ECOG (0–5)a 4 (1–4), n = 129 4 (3–4), n = 11
Barthel (0–100)a 15 (0–95), n = 138 20 (0–70), n = 12
AEDL (0–36)a 18 (3–36), n = 144 19 (8–35), n = 15
Total Symptom score (0–51)a 15 (5–30), n = 144 14 (8–24), n = 15
aMedian (range)
bSpecialized palliative care unit
cFirst period of LCP care (if discontinued and reincluded later)
dOn admission
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Anecdotal evidence has hinted towards a ten percent
proportion of patients who “may appear briefly to be
dying and then rally to have more time for a variety of
reasons, most of which are social, emotional or spirit-
ual.” [48]. We were able to confirm this number in a
large cohort. The proportion reflects the inherent uncer-
tainties in prognostication of death in which equivocal
evaluation seems to be common even in highly experi-
enced teams [34, 50].
We were able to include two thirds of our dying pa-
tients into the LCP. This is a higher rate than in a recent
systematic review by Stocker and Close where an aver-
age uptake of the LCP of 47.4 % was reported [51]. The
uptake ranges from 34–87 % [12]. Those patients who
were not included in the LCP died a sudden death with-
out prior signs or common phenomena of a terminal
phase [52] as identified by the assessing palliative care
team. A small subgroup of patients was not included
into the LCP due to missing consensus between IPT
members, demonstrating the relevance of active inter-
professional team communication.
Our data show a benefit and necessity for routine IPT
reassessment during care for the dying. This assessment
is an important contributing factor in diagnosing non-
dying patients in the LCP [53]. Interprofessional team-
work has received increasing attention within healthcare
and care for the dying in particular [17, 53]. However, it
takes time to control symptoms, ensure good communi-
cation and support families within a team approach [9].
It takes time to fully assess the patient system and to de-
cide on a treatment plan [25]. Additionally, qualitative
data suggests that integrated care plans can only be as
effective as the degree of routine background accessibil-
ity of expert opinion for difficult cases [53]. Our study
supports the notion that quality interprofessional com-
munication improves care of the dying by stressing the
association between rigorous and routine team discus-
sion and the potential effect on diagnostic accuracy and
survival time. Our data can serve as an indicator for the
degree of uptake of integrated care plans in end-of-life
care and reasons for non-inclusion or discontinuation.
The question remains whether 10 % of misdiagnosing of
dying is a high or low value in this context. Those num-
bers might serve as helpful in the development of quality
criteria and for advanced care planning conversations in
palliative care [54].
Limitations
This study has several limitations. Non-controlled obser-
vational studies provide associations but no robust evi-
dence of cause-effect relations. We found no statistical
indication for confounding or moderation in our data.
However, a trend was observed for the predictive value
of the PPI score and the duration of LCP care justifying
further analysis in future research.
Our study was set in a SPCU although the LCP was pri-
marily designed for non-specialized settings [2]. The con-
text of our study therefore needs to be adequately taken
into consideration in future research studies. On the other
hand, studying integrated care plans in a ‘gold standard’
setting can also provide valuable insights into the impact
of integrated care plans on quality improvement, even in
highly experienced palliative care teams [55].
Fig. 3 Kaplan-Meier estimates of survival for patients who were
discontinued from the LCP compared with patients who were not
discontinued from the LCP. Patients who recovered during the LCP
period of care and were discontinued lived significantly longer than
patients who did not recover and stayed on the LCP (p < 0.0001).
Starting point for this analysis is the beginning of the LCP
Table 3 Test statistics of the binary logistic regression analysesa
B (SE) R2 χ2 df p exp(B) CI (95 %) for exp(B)
Disease category 0.81 (0.63) 0.01 1.66 1 0.198 2.26 0.68–7.78
Karnofsky index 0.36 (0.45) 0.01 0.65 1 0.421 1.43 0.60–3.42
PPI score −0.23 (0.12) 0.45 3.67 1 0.055 0.79 0.62–1.01
LCP duration 0.01 (0.01) 0.02 3.72 1 0.054 1.01 1.00–1.02
R2 (Cox & Snell), χ2 Wald-Test
aBinary regression analysis was performed by adding all variables into the block simultaneously (method = Enter)
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Conclusions
Diagnosing as dying and commencing an integrated
end-of-life care plan (such as the LCP) does not result in
a one-way route to death. Instead, if applied according
to best practice, it is common to see patients stabilising
or recovering during LCP care. We find that with 9.4 %
of our LCP patients, the use of the integrated care plan
was discontinued. Regular interprofessional assessment
is important to identify those patients who stabilise dur-
ing this period of care. Our findings provide no evidence
for harm to patients cared along correctly applied LCP
recommendations. The decision to discontinue the LCP
upon re-assessment is typically correct and discontinued
LCP patients seem to live longer as compared to patients
who stay on the LCP. We conclude that informed and
correct application of the LCP is a useful and safe means
of good care for the dying.
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Fig. 4 Symptom burden over time. The box plots show the distribution
of symptom burden of patients who were first included and
then discontinued from the LCP (n = 15). Patient were assessed
at baseline (admission to the specialized palliative care unit) (t1),
upon LCP inclusion (t2) and when discontinued from the LCP (t3). A,
psychological burden (0–12); B, nausea and vomiting (0–8); C,
dyspnoea (0–4); D, pain (0–10); E, total symptom burden (0–51).
There was no significant change in the symptom burden subscores
during LCP care (V = 0.56; F (8,7) = 1.11; p = 0.45). • = outliers;
* = extreme values
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